Individual Investors

Subscribe to email updates

Subscribe now

Financial Professionals

Subscribe to email updates, or password protected financial professional-only content
email address/username
password

PPH
VanEck Vectors Pharmaceutical ETF

  • Fund Description

    VanEck Vectors Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.

  •  
      

    • Fund Ticker

      PPH
    • Exchange

      NASDAQ
    • Commencement

      12/20/2011
    • ETF Structure

      Physical
    • Administrator

      Van Eck Associates
    • Custodian

      Bank of New York Mellon
    • Index Ticker

      MVPPHTR
    • Index Rebalancing

      Quarterly
  •  
    as of 12/08/16

    • 30-Day SEC Yield1

      1.92%
    • Total Net Assets

      $255.4M
    • Number of Holdings

      26
    • Options

      Available
    • Gross Expense Ratio2

      0.41%
    • Net Expense Ratio/TER2

      0.36%
    • Distribution Frequency

      Quarterly
    • Next Distribution Date

      12/16/2016
  • Key Points

    Highly Liquid Companies 
    Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume
    Industry Leaders
    Index methodology favors the largest companies in the industry
    Global Scope 
    Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation
     
  • Trading Information

    • Fund Ticker

      PPH
    • Index Total Return Ticker

      MVPPHTR
    • NAV

      PPHNV
    • Intraday NAV (IIV)4

      PPHIV
    • Shares Outstanding

      4,988,138
    • Estimated Cash

      PPHEU
    • Total Cash

      PPHTC
    • CUSIP

      92189F692
    • ISIN

      US92189F6925
    Source: Bloomberg
  • Fees and Expenses2

    • Management Fee

      0.35%
    • Other Expenses

      0.06%
    • Gross Expense Ratio

      0.41%
    • Fee Waivers and
      Expense Reimbursement

      -0.05%
    • Net Expense Ratio/TER2

      0.36%
    2 Expenses for PPH are capped contractually at 0.35% until at least February 1, 2017. Cap excludes certain expenses, such as interest.
  • Prices as of 12/08/16

    NAV/
    Last Price
    Volume
    30-Day Avg./
    Last Trading Day
    Daily Change
    NAV/
    Last Price
    YTD Change
    NAV/
    Last Price
    Premium/
    Discount
    Prem/Discount
    Distribution Charts
    NAV &
    Prem/Discount
    History
    NAV
    Chart
    PPH $51.20
    $51.23
    185,876
    76,626
    $0.15 / +0.29%
    $0.16 / +0.31%
    -19.5%
    -19.5%
    $0.03
    0.07%
  • View All IndicesView All ETFsPerformance History: Average Annual Total Returns* (%)

    1 MO*3 MO*YTD*1 YR3 YR5 YR10 YRLIFE
    12/20/11
    PPH (NAV)-0.04-11.71-18.81-18.071.82----10.10
    PPH (Share Price)0.06-11.61-18.84-18.101.81----10.34
    MVPPHTR (Index)-0.06-11.70-19.00-17.991.8210.60--10.05
    Performance Differential (NAV - Index)0.02-0.010.19-0.080.00----0.05
    Quarter End as of 09/30/16
    1 MO*3 MO*YTD*1 YR3 YR5 YR10 YRLIFE
    12/20/11
    PPH (NAV)-2.46-1.63-10.31-6.728.38----12.80
    PPH (Share Price)-2.39-1.51-10.38-6.638.43----13.04
    MVPPHTR (Index)-2.45-1.60-10.51-6.648.3914.12--12.75
    Performance Differential (NAV - Index)-0.01-0.030.20-0.08-0.01----0.05
  • Daily HoldingsTop 10 Holdings (%)  as of 11/30/16

    Total Holdings: 26
    Holding Name
    Ticker
    SharesMarket Value
    (US$)
    % of Net
    Assets
    Sanofi
    SNY US
    373,187
    15,002,1175.81
    Bristol-Myers Squibb Co
    BMY US
    261,228
    14,743,7085.71
    Merck & Co Inc
    MRK US
    235,057
    14,383,1385.57
    Abbvie Inc
    ABBV US
    227,471
    13,830,2375.35
    Johnson & Johnson
    JNJ US
    123,536
    13,749,5575.32
    Pfizer Inc
    PFE US
    424,166
    13,632,6955.28
    Zoetis Inc
    ZTS US
    255,603
    12,877,2794.98
    Glaxosmithkline Plc
    GSK US
    337,262
    12,745,1314.93
    Novartis Ag
    NVS US
    183,884
    12,643,8644.89
    Abbott Laboratories
    ABT US
    317,447
    12,085,2074.68
    Top 10 Total (%)52.52
    These are not recommendations to buy or to sell any security. Securities and holdings may vary.
  • Country Weightings (%) as of 11/30/16

    • Country

      % of Net Assets
    • UNITED STATES

      70.52
    • UNITED KINGDOM

      10.73
    • FRANCE

      5.81
    • SWITZERLAND

      4.89
    • DENMARK

      4.19
    • ISRAEL

      3.78
    • Other/Cash

      0.07
  • Sector Weightings (%) as of 11/30/16

    • Sector

      % of Net Assets
    • Health Care

      99.9
    • Other/Cash

      0.1